After calculating the individualized CD8+ to CD4+ T-cell ratio as a suitable surrogate of tumor immune activation, the results show that this ratio was significantly elevated in tumors treated with Ad5/11-αCD3TAT-Trimer. The gene discussed is CD8A; the disease is neoplasm.